Andreu Prados

About Andreu Prados

Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

A recent review, led by Prof. Peter Turnbaugh from the Department of Microbiology & Immunology at University of California San Francisco (USA), discusses several mechanisms that link the gut microbiota with xenobiotic metabolism, and explores how this knowledge can be applied to improve the treatment of human disease.

A recent study, led by Dr. Josef Anrather, an associate professor of neuroscience at the Weill Cornell Medical College in New York (USA), has found that the commensal gut microbiota could influence the immune system to decrease the severity of ischemic stroke in mice.

A recent study has found that the anti-atherosclerosis effects of resveratrol (RSV) - a plant-based natural phenolic compound used to fight pathogens such as fungi and bacteria - are related to changes in the gut microbiota of mice.

A recent review, published by assistant professor Suzanne Devkota at Cedars-Sinai Medical Centre in Los Angeles (USA), have shed light on the importance of controlling for external factors in microbiome studies, focusing on medications that could have confounding effects.  

A recent study, led by Prof. Peter Holzer from the Research Unit of Translational Neurogastroenterology at Medical University of Graz in Austria, has found that intragastric treatment of mice with an antibiotic mixture impaired novel object recognition. This cognitive effect was associated with a disruption of the microbial communities in the colon, a depletion of bacteria-derived metabolites in the colon, and particular changes of neurochemical brain activity.

Faecal microbiota transplantation has been demonstrated to be a safe and highly effective therapeutic option for refractory C. difficile infection (CDI), and many studies have shown that it may possibly have applications in other illnesses such as inflammatory bowel disease (IBD) and in particular for ulcerative colitis (UC).

A recent study, led by Dr. Tine Rask Licht, head of the Research Group for Microbiology and Immunology from the National Food Institute at Technical University of Denmark, found that the development and establishment of the infant gut microbiota at 9 months of age is primarily driven by the transition to family foods, independently of maternal obesity.

A novel review, led by Dr. Andrés Moya from the University of Valencia (Spain) and Dr. Manuel Ferrer from the Institute of Catalysis at Spanish National Research Council in Madrid (Spain), argues that a network-biology approach can help us understand how our gut microbiota is continuously changing in the gut environment.